This aspect is remarkable since in patients who carry MLH1 gene pathogenic variants, the somatic tumor hypermethylation of the MLH1 gene promoter is always associated with the loss of MLH1 and PMS2 proteins expression. Here, MLH1 is linked to neoplasm.